Gwendolyn H Ho, MD
Hematology/Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ho’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$694,128
Medicare paid this office $694,128 for 220 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 88 | $32,210 | $162 |
| Return visit (30+ min) | 106 | $21,706 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $11,800 | $139 |
| New patient visit (60+ min) | 25 | $4,553 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,444 | $153 |
See all 13 services
| Long return visit (40+ min) | 88 | $32,210 | $162 |
| Return visit (30+ min) | 106 | $21,706 | $111 |
| Administration of chemotherapy into vein, 1 hour or less | 19 | $11,800 | $139 |
| New patient visit (60+ min) | 25 | $4,553 | $182 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $4,444 | $153 |
| New patient visit (45+ min) | 34 | $4,094 | $120 |
| Short return visit (20+ min) | 40 | $3,444 | $77 |
| Injection of additional new drug or substance into vein | 14 | $1,843 | $15 |
| Administration of chemotherapy into vein, each additional hour | 11 | $1,473 | $27 |
| Injection of drug or substance under skin or into muscle | 15 | $1,120 | $13 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $701 | $37 |
| Infusion, normal saline solution , 1000 cc | 27 | $336 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $68 | None |
Who their Medicare patients are
220 Original Medicare patients in 2024. Average age 77 · Women 49% · Also on Medicaid 19% · Health risk score 1.77. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 69% · Cancer 37% · Coronary heart disease 29% · Heart failure 22% · Atrial fibrillation 22% · Chronic kidney disease 20% · Diabetes 16% · Depression 16% · Stroke 15% · COPD 11% · Dementia 8%.
The office billed $2,364,213, Medicare allowed $878,961 and paid $694,128; for 48,470 services of 73 kinds; $590,007 of it was for drugs given in the office and $104,121 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 220 | 48,470 | 77 | 1.77 | $2,364,213 | $694,128 |
| 2023 | 285 | 97,743 | 76 | 1.67 | $3,696,483 | $1,059,159 |
| 2022 | 125 | 26,644 | 78 | 1.20 | $1,453,975 | $441,499 |
| 2021 | 12 | 892 | 66 | 1.65 | $126,301 | $33,129 |
| 2020 | 11 | 687 | 62 | 2.68 | $95,932 | $24,614 |
| 2019 | 13 | 669 | 65 | 2.01 | $112,143 | $27,175 |
| 2018 | 15 | 1,195 | 62 | 1.79 | $133,774 | $31,598 |
| 2017 | 11 | 24 | 65 | 2.06 | $4,865 | $1,224 |
| 2016 | 14 | 15 | 71 | 3.32 | $3,980 | $1,132 |
| 2014 | 84 | 150 | 68 | 3.05 | $37,114 | $10,791 |
| 2013 | 72 | 75 | 67 | 1.84 | $17,127 | $4,400 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 21 services
| Long return visit (40+ min) | 101 | $53,052 | $163 |
| Return visit (30+ min) | 107 | $36,095 | $114 |
| Administration of chemotherapy into vein, 1 hour or less | 30 | $24,179 | $138 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 20 | $11,342 | $0 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 56 | $10,009 | $154 |
| New patient visit (45+ min) | 67 | $9,883 | $148 |
| New patient visit (60+ min) | 44 | $8,779 | $200 |
| Administration of chemotherapy into vein, each additional hour | 26 | $7,611 | $28 |
| Injection of additional new drug or substance into vein | 24 | $6,297 | $16 |
| Short return visit (20+ min) | 59 | $5,820 | $76 |
| Administration of additional new drug or substance into vein, 1 hour or less | 17 | $5,402 | $68 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $4,120 | $106 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 15 | $3,008 | $177 |
| Injection of drug or substance into vein | 26 | $2,706 | $37 |
| Injection of drug or substance under skin or into muscle | 24 | $2,122 | $14 |
| Infusion into a vein for hydration, 31-60 minutes | 12 | $1,320 | $34 |
| Infusion, normal saline solution , 1000 cc | 42 | $727 | None |
| Injection, palonosetron hcl, 25 mcg | 15 | $605 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 21 | $234 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $61 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 18 | $59 | None |
2022: 12 services
| Long return visit (40+ min) | 35 | $15,371 | $167 |
| Administration of chemotherapy into vein, 1 hour or less | 17 | $12,981 | $141 |
| Return visit (30+ min) | 47 | $11,937 | $119 |
| New patient visit (45+ min) | 53 | $8,001 | $151 |
| New patient visit (60+ min) | 27 | $5,291 | $196 |
| Administration of chemotherapy into vein, each additional hour | 14 | $3,893 | $29 |
| Injection of additional new drug or substance into vein | 16 | $3,033 | $16 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,977 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 15 | $2,790 | $174 |
| Short return visit (20+ min) | 29 | $2,604 | $84 |
| Injection, dexamethasone sodium phosphate, 1 mg | 13 | $88 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $38 | None |
2014: 4 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,599 | $84 |
| Return visit (30+ min) | 42 | $2,476 | $54 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $930 | $58 |
| Hospital discharge day management, 30 minutes or less | 11 | $705 | $59 |
2013: 1 service
| Return visit (30+ min) | 61 | $3,786 | $59 |
Medicaid work
$11,203 in 2024
Medicaid paid $11,203 for 154 billed services this clinician did in 2024, up to 23 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 127 | $9,746 |
| Return visit (30+ min) | 27 | $1,457 |
| 2024 | 154 | 2 | 23 | $11,203 |
| 2023 | 74 | 1 | 16 | $6,561 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 74 | $6,561 |
Drugs they prescribed that Part D paid
$875,766
Pharmacies billed $875,766 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 6% of their Part D prescriptions (25 of 448) in 2024. Above the middle of the specialty; the typical hematology-oncology clinician is at 5%.
346 generic and 102 brand-name prescriptions · $875,766 in drug cost · 15 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brukinsa | 24 | $259,583 | $10,816 |
| Orgovyx | 16 | $44,823 | $2,801 |
| Venclexta | 11 | $42,869 | $3,897 |
| Abiraterone Acetate | 38 | $17,240 | $454 |
| Hydroxyurea | 32 | $1,008 | $31 |
See all 11 drugs
| Brukinsa | 24 | $259,583 | $10,816 |
| Orgovyx | 16 | $44,823 | $2,801 |
| Venclexta | 11 | $42,869 | $3,897 |
| Abiraterone Acetate | 38 | $17,240 | $454 |
| Hydroxyurea | 32 | $1,008 | $31 |
| Letrozole | 23 | $667 | $29 |
| Ondansetron Odt | 26 | $377 | $15 |
| Prednisone | 41 | $257 | $6 |
| Dexamethasone | 13 | $246 | $19 |
| Prochlorperazine Maleate | 15 | $208 | $14 |
| Lorazepam | 13 | $87 | $7 |
Year by year
| 2024 | 448 | 100 | 6% (25) | 23% | $875,766 |
| 2023 | 648 | 127 | 6% (36) | None | $971,190 |
| 2022 | 627 | 183 | 9% (56) | None | $1,072,120 |
| 2021 | 926 | 183 | 9% (79) | 23% | $2,580,767 |
| 2020 | 808 | 171 | 7% (60) | 23% | $2,144,482 |
| 2019 | 1,037 | 173 | 8% (85) | 27% | $3,026,319 |
| 2018 | 760 | 141 | 10% (72) | 30% | $2,079,801 |
| 2017 | 379 | 70 | 20% (74) | 21% | $343,658 |
| 2016 | 404 | 51 | 17% (68) | None | $214,704 |
| 2015 | 420 | 61 | 13% (56) | None | $249,228 |
| 2014 | 381 | 84 | 13% (48) | None | $118,321 |
| 2013 | 637 | 79 | 16% (103) | 28% | $41,149 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 17 drugs
| Ibrance | 13 | $230,081 | $17,699 |
| Abiraterone Acetate | 47 | $193,117 | $4,109 |
| Brukinsa | 12 | $182,657 | $15,221 |
| Hydroxyurea | 48 | $2,550 | $53 |
| Acyclovir | 16 | $741 | $46 |
| Ondansetron Odt | 26 | $608 | $23 |
| Letrozole | 27 | $592 | $22 |
| Prednisone | 83 | $521 | $6 |
| Dexamethasone | 26 | $484 | $19 |
| Hydrocodone-Acetaminophen | 16 | $467 | $29 |
| Prochlorperazine Maleate | 24 | $278 | $12 |
| Mirtazapine | 11 | $239 | $22 |
| Ondansetron | 21 | $225 | $11 |
| Levofloxacin | 16 | $203 | $13 |
| Furosemide | 19 | $113 | $6 |
| Lorazepam | 15 | $92 | $6 |
| Trazodone | 12 | $68 | $6 |
2022: 15 drugs
| Ibrance | 24 | $330,168 | $13,757 |
| Abiraterone Acetate | 20 | $99,410 | $4,970 |
| Eliquis | 14 | $7,926 | $566 |
| Hydroxyurea | 58 | $3,585 | $62 |
| Letrozole | 60 | $1,325 | $22 |
| Anastrozole | 39 | $977 | $25 |
| Dexamethasone | 14 | $394 | $28 |
| Ondansetron | 21 | $349 | $17 |
| Ondansetron Odt | 12 | $346 | $29 |
| Prochlorperazine Maleate | 28 | $296 | $11 |
| Prednisone | 33 | $237 | $7 |
| Alendronate | 16 | $166 | $10 |
| Tramadol | 12 | $88 | $7 |
| Furosemide | 13 | $82 | $6 |
| Lorazepam | 18 | $61 | $3 |
2021: 23 drugs
| Revlimid | 40 | $644,444 | $16,111 |
| Ibrance | 42 | $528,702 | $12,588 |
| Imbruvica | 30 | $437,050 | $14,568 |
| Pomalyst | 11 | $227,856 | $20,714 |
| Venclexta | 11 | $94,824 | $8,620 |
| Zarxio | 14 | $13,039 | $931 |
| Hydroxyurea | 67 | $4,216 | $63 |
| Imatinib Mesylate | 12 | $3,146 | $262 |
| Letrozole | 113 | $2,787 | $25 |
| Dexamethasone | 55 | $1,556 | $28 |
| Anastrozole | 60 | $1,467 | $24 |
| Exemestane | 16 | $1,334 | $83 |
| Acyclovir | 36 | $1,057 | $29 |
| Ondansetron | 44 | $507 | $12 |
| Prednisone | 42 | $414 | $10 |
| Gabapentin | 17 | $349 | $21 |
| Hydrocodone-Acetaminophen | 19 | $308 | $16 |
| Hydromorphone | 11 | $295 | $27 |
| Prochlorperazine Maleate | 11 | $248 | $23 |
| Tramadol | 23 | $189 | $8 |
| Trazodone | 12 | $168 | $14 |
| Alendronate | 15 | $156 | $10 |
| Lorazepam | 16 | $120 | $8 |
2020: 18 drugs
| Revlimid | 45 | $692,723 | $15,394 |
| Ibrance | 39 | $501,205 | $12,851 |
| Imbruvica | 21 | $281,255 | $13,393 |
| Exemestane | 15 | $4,033 | $269 |
| Imatinib Mesylate | 17 | $3,339 | $196 |
| Hydroxyurea | 53 | $2,636 | $50 |
| Dexamethasone | 61 | $2,412 | $40 |
| Letrozole | 97 | $2,391 | $25 |
| Anastrozole | 61 | $1,491 | $24 |
| Hydrocodone-Acetaminophen | 23 | $591 | $26 |
| Acyclovir | 13 | $589 | $45 |
| Prochlorperazine Maleate | 14 | $374 | $27 |
| Ondansetron | 31 | $313 | $10 |
| Gabapentin | 12 | $257 | $21 |
| Diphenoxylate-Atropine | 11 | $248 | $23 |
| Furosemide | 17 | $133 | $8 |
| Alendronate | 12 | $125 | $10 |
| Lorazepam | 16 | $123 | $8 |
2019: 24 drugs
| Ibrance | 103 | $1,327,962 | $12,893 |
| Revlimid | 61 | $922,245 | $15,119 |
| Jakafi | 15 | $307,972 | $20,531 |
| Imbruvica | 18 | $216,334 | $12,019 |
| Zarxio | 26 | $40,485 | $1,557 |
| Imatinib Mesylate | 21 | $3,855 | $184 |
| Exemestane | 13 | $3,329 | $256 |
| Letrozole | 112 | $2,729 | $24 |
| Dexamethasone | 82 | $2,598 | $32 |
| Entecavir | 19 | $2,392 | $126 |
| Hydroxyurea | 47 | $2,143 | $46 |
| Anastrozole | 66 | $1,593 | $24 |
| Tamoxifen Citrate | 15 | $861 | $57 |
| Hydrocodone-Acetaminophen | 34 | $748 | $22 |
| Hydromorphone | 14 | $627 | $45 |
| Venlafaxine | 13 | $410 | $32 |
| Prednisone | 46 | $402 | $9 |
| Ondansetron | 42 | $401 | $10 |
| Prochlorperazine Maleate | 24 | $390 | $16 |
| Gabapentin | 17 | $320 | $19 |
| Lorazepam | 30 | $216 | $7 |
| Furosemide | 13 | $135 | $10 |
| Tramadol | 11 | $131 | $12 |
| Allopurinol | 11 | $122 | $11 |
2018: 17 drugs
| Ibrance | 90 | $1,108,193 | $12,313 |
| Revlimid | 30 | $411,132 | $13,704 |
| Imbruvica | 25 | $292,725 | $11,709 |
| Zarxio | 27 | $60,856 | $2,254 |
| Letrozole | 79 | $1,903 | $24 |
| Dexamethasone | 50 | $1,331 | $27 |
| Anastrozole | 31 | $812 | $26 |
| Hydrocodone-Acetaminophen | 37 | $734 | $20 |
| Hydroxyurea | 12 | $536 | $45 |
| Ondansetron | 25 | $394 | $16 |
| Prednisone | 37 | $315 | $9 |
| Prochlorperazine Maleate | 25 | $262 | $10 |
| Lorazepam | 30 | $237 | $8 |
| Famotidine | 11 | $173 | $16 |
| Furosemide | 21 | $138 | $7 |
| Trazodone | 12 | $107 | $9 |
| Allopurinol | 11 | $87 | $8 |
2017: 9 drugs
| Imbruvica | 15 | $151,275 | $10,085 |
| Enoxaparin | 13 | $9,167 | $705 |
| Hydrocodone-Acetaminophen | 40 | $745 | $19 |
| Oxycodone | 15 | $509 | $34 |
| Letrozole | 19 | $390 | $21 |
| Ondansetron | 14 | $285 | $20 |
| Lorazepam | 34 | $219 | $6 |
| Acyclovir | 12 | $116 | $10 |
| Sulfamethoxazole-Trimethoprim | 12 | $32 | $3 |
2016: 11 drugs
| Neupogen | 13 | $33,904 | $2,608 |
| Hydrocodone-Acetaminophen | 37 | $1,530 | $41 |
| Polyethylene Glycol 3350 | 11 | $307 | $28 |
| Oxycodone | 19 | $286 | $15 |
| Ondansetron | 22 | $224 | $10 |
| Pantoprazole | 12 | $127 | $11 |
| Lorazepam | 29 | $122 | $4 |
| Prochlorperazine Maleate | 16 | $94 | $6 |
| Amlodipine Besylate | 20 | $93 | $5 |
| Famotidine | 14 | $36 | $3 |
| Furosemide | 11 | $25 | $2 |
2015: 9 drugs
| Baraclude | 11 | $11,669 | $1,061 |
| Hydrocodone-Acetaminophen | 26 | $1,242 | $48 |
| Ondansetron | 34 | $541 | $16 |
| Oxycodone | 14 | $261 | $19 |
| Pantoprazole | 21 | $175 | $8 |
| Lorazepam | 31 | $143 | $5 |
| Prednisone | 16 | $130 | $8 |
| Prochlorperazine Maleate | 15 | $85 | $6 |
| Potassium Chloride | 11 | $77 | $7 |
2014: 9 drugs
| Morphine Sulfate Er | 11 | $2,760 | $251 |
| Pravastatin | 18 | $434 | $24 |
| Hydrocodone-Acetaminophen | 17 | $380 | $22 |
| Ondansetron | 19 | $353 | $19 |
| Gabapentin | 14 | $244 | $17 |
| Levothyroxine | 13 | $202 | $16 |
| Atorvastatin | 11 | $159 | $14 |
| Lorazepam | 20 | $85 | $4 |
| Lisinopril | 11 | $45 | $4 |
2013: 18 drugs
| Lantus | 22 | $4,261 | $194 |
| Novolog | 12 | $2,917 | $243 |
| Morphine Sulfate Er | 26 | $1,661 | $64 |
| Hydrocodone-Acetaminophen | 59 | $1,273 | $22 |
| Gabapentin | 27 | $1,253 | $46 |
| Divalproex | 13 | $1,220 | $94 |
| Xopenex Hfa | 15 | $751 | $50 |
| Omeprazole | 22 | $510 | $23 |
| Montelukast | 11 | $505 | $46 |
| Metoprolol | 12 | $428 | $36 |
| Polyethylene Glycol 3350 | 12 | $398 | $33 |
| Synthroid | 11 | $273 | $25 |
| Amlodipine Besylate | 25 | $212 | $8 |
| Lisinopril | 26 | $173 | $7 |
| Levothyroxine | 14 | $166 | $12 |
| Hydrochlorothiazide | 13 | $108 | $8 |
| Metformin | 13 | $99 | $8 |
| Metoprolol | 16 | $97 | $6 |
Money from drug and device companies
$36 in 2025
| 2025 | 2 | 2 | None | $36 |
| 2023 | 2 | 2 | None | $40 |
| 2022 | 1 | 2 | None | $29 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Daiichi Sankyo | Enhertu | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $17 | 1 payment
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-17 | Enhertu | $17 |
| Daiichi Sankyo | Meals · 2025-10-16 | Enhertu | $18 |
See earlier years (2023, 2022)
2023: $40
| Pfizer | Ibrance | $25 | 1 payment
|
| EMD Serono | Tepmetko | $15 | 1 payment
|
2022: $29
| Celgene | Reblozyl | $29 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · A Phase 2 Study To Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase Mk-3475a Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types Mk-3475a-F11 · 2024 | Their institution | $188,249 |
| Merck Sharp & Dohme LLC · A Phase 2 Study To Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase Mk-3475a Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types Mk-3475a-F11 · 2023 | Their institution | $149 |
Professional record
- NPI
- 1487970547
- Licence
- CA A1189808
- Trained
- University of California, San Francisco School of Medicine, 2010
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Internal medicine (207R00000X); Medical oncology (207RX0202X)
- Mailing address
- 2589 Samaritan Dr, San Jose, CA, 95124
- NPI first listed
- 2010-04-14
- NPI last updated
- 2025-01-23
- NPI record certified
- 2025-01-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4501 X St Ste 3016, Sacramento, CA, 95817
This office lists an electronic records connection.